IL33 and prostate carcinoma: In this work, we found that ILC2s and the ILC2-activating cytokines IL-33 and IL-18 are increased both in the tumor microenvironment and in the circulation of patients with PCa, suggesting that, also in prostate cancer, one of the most prevalent forms of cancer in men worldwide, they exert a protumoral function.